China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics
China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world.
The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.
China’s diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.
IMARC’s new report “China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Chinese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.
What we have achieved in this report:
Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:
Focus of the Analysis:
Focus of the Analysis:
Focus of the Analysis:
Focus of the Analysis:
The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.
China’s diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.
IMARC’s new report “China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Chinese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.
What we have achieved in this report:
Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:
Focus of the Analysis:
- Historical, current and future prevalence of diabetes in China
- Historical, current and future prevalence of type-1 and type-2 diabetes in China
- Historical, current and future prevalence of diabetes in the urban and rural regions in China
- Historical, current and future prevalence of diabetes among males and females in China
- Historical, current and future prevalence of diabetes among various age groups in China
- Historical, current and future diagnosis rates for diabetes in China
- Historical, current and future drug treatment rates for diabetes in China
Focus of the Analysis:
- Performance of the Oral Antidiabetics market in China
- Performance of key classes
- Performance of key players
- Market outlook
Focus of the Analysis:
- Performance of the Insulin market in China
- Performance of key classes
- Performance of key players
- Market outlook
Focus of the Analysis:
- Performance of the diabetes diagnostics market in China
- Market Segmentation
- Key players
- Market outlook
1 PREFACE
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 DIABETES DISEASE OVERVIEW
5.1 What is Diabetes?
5.2 Diabetes Diagnosis and Treatment
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Diabetes Complications
6 CHINA DIABETES EPIDEMIOLOGY
6.1 Diabetes Population and Prevalence Rates
6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
6.3 Population and Prevalence Rates by Region
6.4 Population and Prevalence Rates by Gender
6.5 Population and Prevalence Rates by Age Group
7 CHINA DIABETES MARKET
7.1 Market Overview
7.2 Market Performance
7.3 Market Forecast
7.4 SWOT Analysis
7.4.1 Strengths
7.4.2 Weaknesses
7.4.3 Opportunities
7.4.4 Threats
7.5 Value Chain Analysis
7.6 Porter’s Five Forces Analysis
7.6.1 Overview
7.6.2 Bargaining Power of Buyers
7.6.3 Bargaining Power of Suppliers
7.6.4 Degree of Competition
7.6.5 Threat of New Entrants
7.6.6 Threat of Substitutes
7.7 Market Breakup by Segment
7.7.1 China Oral Antidiabetics Market
7.7.1.1 Historical Market Trends
7.7.1.2 Market Breakup by Class
7.7.1.3 Market Shares of Key Players
7.7.1.4 Market Forecast
7.7.2 China Insulin Market
7.7.2.1 Historical Market Trends
7.7.2.2 Market Breakup by Class
7.7.2.3 Market Shares of Key Players
7.7.2.4 Market Forecast
7.8 Competitive Landscape
7.8.1 Competitive Structure
7.8.2 Profiles of Key Players
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 DIABETES DISEASE OVERVIEW
5.1 What is Diabetes?
5.2 Diabetes Diagnosis and Treatment
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Diabetes Complications
6 CHINA DIABETES EPIDEMIOLOGY
6.1 Diabetes Population and Prevalence Rates
6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
6.3 Population and Prevalence Rates by Region
6.4 Population and Prevalence Rates by Gender
6.5 Population and Prevalence Rates by Age Group
7 CHINA DIABETES MARKET
7.1 Market Overview
7.2 Market Performance
7.3 Market Forecast
7.4 SWOT Analysis
7.4.1 Strengths
7.4.2 Weaknesses
7.4.3 Opportunities
7.4.4 Threats
7.5 Value Chain Analysis
7.6 Porter’s Five Forces Analysis
7.6.1 Overview
7.6.2 Bargaining Power of Buyers
7.6.3 Bargaining Power of Suppliers
7.6.4 Degree of Competition
7.6.5 Threat of New Entrants
7.6.6 Threat of Substitutes
7.7 Market Breakup by Segment
7.7.1 China Oral Antidiabetics Market
7.7.1.1 Historical Market Trends
7.7.1.2 Market Breakup by Class
7.7.1.3 Market Shares of Key Players
7.7.1.4 Market Forecast
7.7.2 China Insulin Market
7.7.2.1 Historical Market Trends
7.7.2.2 Market Breakup by Class
7.7.2.3 Market Shares of Key Players
7.7.2.4 Market Forecast
7.8 Competitive Landscape
7.8.1 Competitive Structure
7.8.2 Profiles of Key Players
LIST OF FIGURES
Figure 1: The Impact of Diabetes in the Human Body
Figure 2: Diabetes Complications
Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2016 & 2035
Figure 4: China: Overweight & Obese Population (in Million), 2010, 2016 & 2022
Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 6: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in %)
Figure 7: China: Diabetes Prevalence By Age Groups, (in %)
Figure 8: China: Total Number of Diabetes Patients (in 000), 2009-2016
Figure 9: China: Total Number of Diabetes Patients Forecast (in 000), 2017-2022
Figure 10: China (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2009- 2016
Figure 11: China (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2017-2022
Figure 12: China (Urban & Rural): Total Number of Diabetes Patients (in 000), 2009 -2022
Figure 13: China (Urban & Rural): Total Number of Diabetes Patients (in 000), 2017 - 2022
Figure 14: China (Male & Female): Total Number of Diabetes Patients (in 000), 2009 - 2016
Figure 15: China (Male & Female): Total Number of Diabetes Patients (in 000), 2017 - 2022
Figure 16: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2009 - 2016
Figure 17: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2017 – 2022
Figure 18: China: Diabetes Drug Industry Overview
Figure 19: China: Diabetes Drug Market (in Million US$), 2009 - 2016
Figure 20: China: Diabetes Drug Market Forecast (in Million US$), 2017 – 2022
Figure 21: China: Diabetes Drug Market: SWOT Analysis
Figure 22: China: Diabetes Drug Market: Value Chain Analysis
Figure 23: China: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: China: Diabetes Drugs Market: Breakup of Insulin and Oral Antidiabetics (in %), 2009 - 2016
Figure 25: China: Diabetes Drugs Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2017 - 2022
Figure 26: China: Oral Antidiabetics Market: (in Million US$), 2009 - 2016
Figure 27: China: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2009 & 2016
Figure 28: China: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
Figure 29: China: Oral Antidiabetics Market: (in Million US$), 2017 - 2022
Figure 30: China: Insulin Market, (in Million US$), 2009 - 2016
Figure 31: China: Breakup of Insulin Market by Class (in %)
Figure 32: China: Insulin Market: Sales Share of Key Players (in %)
Figure 33: China: Insulin Market Forecast (in Million US$), 2017 - 2022
Figure 1: The Impact of Diabetes in the Human Body
Figure 2: Diabetes Complications
Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2016 & 2035
Figure 4: China: Overweight & Obese Population (in Million), 2010, 2016 & 2022
Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 6: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in %)
Figure 7: China: Diabetes Prevalence By Age Groups, (in %)
Figure 8: China: Total Number of Diabetes Patients (in 000), 2009-2016
Figure 9: China: Total Number of Diabetes Patients Forecast (in 000), 2017-2022
Figure 10: China (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2009- 2016
Figure 11: China (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2017-2022
Figure 12: China (Urban & Rural): Total Number of Diabetes Patients (in 000), 2009 -2022
Figure 13: China (Urban & Rural): Total Number of Diabetes Patients (in 000), 2017 - 2022
Figure 14: China (Male & Female): Total Number of Diabetes Patients (in 000), 2009 - 2016
Figure 15: China (Male & Female): Total Number of Diabetes Patients (in 000), 2017 - 2022
Figure 16: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2009 - 2016
Figure 17: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2017 – 2022
Figure 18: China: Diabetes Drug Industry Overview
Figure 19: China: Diabetes Drug Market (in Million US$), 2009 - 2016
Figure 20: China: Diabetes Drug Market Forecast (in Million US$), 2017 – 2022
Figure 21: China: Diabetes Drug Market: SWOT Analysis
Figure 22: China: Diabetes Drug Market: Value Chain Analysis
Figure 23: China: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: China: Diabetes Drugs Market: Breakup of Insulin and Oral Antidiabetics (in %), 2009 - 2016
Figure 25: China: Diabetes Drugs Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2017 - 2022
Figure 26: China: Oral Antidiabetics Market: (in Million US$), 2009 - 2016
Figure 27: China: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2009 & 2016
Figure 28: China: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
Figure 29: China: Oral Antidiabetics Market: (in Million US$), 2017 - 2022
Figure 30: China: Insulin Market, (in Million US$), 2009 - 2016
Figure 31: China: Breakup of Insulin Market by Class (in %)
Figure 32: China: Insulin Market: Sales Share of Key Players (in %)
Figure 33: China: Insulin Market Forecast (in Million US$), 2017 - 2022
LIST OF TABLES
Table 1: Diagnosis of Diabetes
Table 2: Global: Diabetes Population Breakup by Country (in 000’s), 2016 & 2035
Table 3: China: Overweight &Obesity Statistics, 2010, 2016 & 2022
Table 4: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in Million)
Table 5: China: Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 6: China (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 7: China (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 8: China (Male & Female): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 9: China: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2009, 2016 & 2022
Table 10: China: Diabetes Drug Market: Competitive Structure
Table 1: Diagnosis of Diabetes
Table 2: Global: Diabetes Population Breakup by Country (in 000’s), 2016 & 2035
Table 3: China: Overweight &Obesity Statistics, 2010, 2016 & 2022
Table 4: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in Million)
Table 5: China: Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 6: China (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 7: China (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 8: China (Male & Female): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 9: China: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2009, 2016 & 2022
Table 10: China: Diabetes Drug Market: Competitive Structure
